

# Medicines and Healthcare products Regulatory Agency

## MANUFACTURER'S AUTHORISATION

|   |  |
|---|--|
| <b>1: Authorisation Number</b>  | UK MIA(IMP) 22352  |
| <b>2: Name of authorisation holder</b>  | VERTEX PHARMACEUTICALS (EUROPE) LIMITED  |
| <b>3: Address(es) of manufacturing site(s)</b>  | VERTEX PHARMACEUTICALS (EUROPE) LIMITED, LEVEL 9, PADDINGTON CENTRAL, 2 KINGDOM STREET, LONDON, W2 6BD, UNITED KINGDOM |
| <b>4: Legally registered address of authorisation holder</b>  | VERTEX PHARMACEUTICALS (EUROPE) LIMITED, LEVEL 9, PADDINGTON CENTRAL, 2 KINGDOM STREET, LONDON, W2 6BD, UNITED KINGDOM |
| <b>5: Scope of authorisation and dosage forms</b>   | ANNEX 1 and/ or ANNEX 2  |
| <b>6: Legal Basis of authorisation</b>  | Part 6 of The Medicines for Human Use (Clinical Trials) Regulations 2004 [SI 2004/1031]                                |
| <b>7: Name of responsible officer of the competent authority of the member state granting the manufacturing authorisation</b> | Confidential   |
| <b>8: Authorisation Date</b>  | 19/03/2024   |
| <b>9: Annexes attached</b>  | Annex 1 and/or Annex 2   |

### SCOPE OF AUTHORISATION

#### Annex 2

Name and address of the site:

**VERTEX PHARMACEUTICALS (EUROPE) LIMITED, LEVEL 9, PADDINGTON CENTRAL, 2 KINGDOM STREET, LONDON, W2 6BD, UNITED KINGDOM**

|  |
|--|
| Human Investigational Medicinal Products   |
| Authorised Operations  |
| MANUFACTURING OPERATIONS (according to part 1)<br>IMPORTATION OF MEDICINAL PRODUCTS (according to part 2)  |
| <b>Part 1 - MANUFACTURING OPERATIONS</b><br><b>[ 1.3 ] Biological investigational medicinal products</b><br>[ 1.3.2 ] Batch certification<br>[ 1.3.2.3 ] Cell therapy products<br>[ 1.3.2.4 ] Gene therapy products<br><b>Part 2 - IMPORTATION OF MEDICINAL PRODUCTS</b> |

**[ 2.2 ] Batch certification of imported medicinal products**

[ 2.2.2 ] Non-sterile products

[ 2.2.3 ] Biological medicinal products

[ 2.2.3.3 ] Cell therapy products

[ 2.2.3.4 ] Gene therapy products

**[ 2.3 ] Other Importation Activities**

[ 2.3.4 ] Other

Importation of Autologous drug product into Authorised Treatment Centers in the UK